P
40.89
-1.68 (-3.95%)
| Previous Close | 42.57 |
| Open | 41.44 |
| Volume | 1,577,271 |
| Avg. Volume (3M) | 1,083,501 |
| Market Cap | 2,610,577,152 |
| Price / Earnings (TTM) | 9.67 |
| Price / Earnings (Forward) | 26.39 |
| Price / Sales | 6.38 |
| Price / Book | 3.87 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 9 May 2025 |
| Profit Margin | 63.34% |
| Operating Margin (TTM) | 74.30% |
| Diluted EPS (TTM) | 4.07 |
| Quarterly Revenue Growth (YOY) | 184.40% |
| Quarterly Earnings Growth (YOY) | 381.70% |
| Total Debt/Equity (MRQ) | 1.61% |
| Current Ratio (MRQ) | 12.48 |
| Operating Cash Flow (TTM) | 184.15 M |
| Levered Free Cash Flow (TTM) | 65.11 M |
| Return on Assets (TTM) | 28.66% |
| Return on Equity (TTM) | 54.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Protagonist Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
0.8
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.75 |
|
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.38% |
| % Held by Institutions | 105.29% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Johnson & Johnson | 31 Dec 2024 | 2,449,183 |
| Jefferies Financial Group Inc. | 31 Dec 2024 | 1,489,495 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 80.00 (HC Wainwright & Co., 95.65%) | Buy |
| Median | 65.50 (60.19%) | |
| Low | 38.00 (Goldman Sachs, -7.07%) | Hold |
| Average | 64.00 (56.52%) | |
| Total | 7 Buy, 1 Hold | |
| Avg. Price @ Call | 47.35 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 10 Apr 2025 | 80.00 (95.65%) | Buy | 40.89 |
| 11 Mar 2025 | 80.00 (95.65%) | Buy | 59.76 | |
| Wedbush | 28 Mar 2025 | 70.00 (71.19%) | Buy | 48.88 |
| BMO Capital | 11 Mar 2025 | 72.00 (76.08%) | Buy | 59.76 |
| Truist Securities | 11 Mar 2025 | 76.00 (85.86%) | Buy | 59.76 |
| Citizens Capital Markets | 10 Mar 2025 | 61.00 (49.18%) | Buy | 55.95 |
| JP Morgan | 04 Mar 2025 | 57.00 (39.40%) | Buy | 38.66 |
| 04 Feb 2025 | 53.00 (29.62%) | Buy | 37.58 | |
| Goldman Sachs | 24 Feb 2025 | 38.00 (-7.07%) | Hold | 36.00 |
| JMP Securities | 07 Feb 2025 | 58.00 (41.84%) | Buy | 38.88 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |